Holen Sie sich die Stockscreener-App
1.706
1.39%
-0.024
Schlusskurs vom Vortag:
$1.73
Offen:
$1.71
24-Stunden-Volumen:
60,074
Relative Volume:
0.03
Marktkapitalisierung:
$127.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.33M
KGV:
-0.9531
EPS:
-1.79
Netto-Cashflow:
$-39.53M
1W Leistung:
+5.31%
1M Leistung:
+9.36%
6M Leistung:
-49.82%
1J Leistung:
-60.33%
1-Tages-Spanne:
$1.69
$1.74
1-Wochen-Bereich:
$1.575
$1.755
52-Wochen-Spanne:
$1.35
$4.965
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Vergleichen Sie ELDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
1.7001 | 129.81M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.37 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.29 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
814.78 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Can Eledon Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Eledon’s tegoprubart shows promise in kidney transplantation trials By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - The Manila Times
Can Eledon Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Update & Verified Entry Point Signals - ulpravda.ru
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3% – Time to Buy? - Defense World
Is Eledon Pharmaceuticals Inc. (2TK) stock a defensive play amid uncertaintyCandlestick Pattern Analysis & Free Expert Stock Watchlists - ulpravda.ru
Midday Stock Roundup: Lantronix Stock up 4.8% Today - Orange County Business Journal
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Eledon Pharmaceuticals Restructures Stake via Pre-Funded Warrant - TipRanks
Midday Stock Roundup: Rivian Down on Production Totals - Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Eledon Pharmaceuticals (STU:2TK) EV-to-OCF : -0.29 (As of Dec. 31, 2025) - GuruFocus
The End of Shots? 5 Biotech Stocks Rethinking Diabetes - Morningstar
Is Eledon Pharmaceuticals Inc. (2TK) stock a buy during volatile marketsProtective Put Strategies & Small Capital Growth Tips - bollywoodhelpline.com
Midday Stock Roundup: Shimmick Corp. climbs 14% - Orange County Business Journal
Sector Rotation Brings Aditya Birla Sun Life Amc Ltd Into FocusSmall Cap Stock Opportunities & Free ETF and Mutual Fund Comparisons - earlytimes.in
Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today? - MSN
Can Eledon Pharmaceuticals Inc. stock double in next 5 yearsStochastic Oscillator Alerts & Free High Yield Growth Strategies - Bollywood Helpline
Eledon Pharmaceuticals Inc (ELDN) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Analysts Set Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Target Price at $9.67 - Defense World
Midday Stock Roundup: Rivian Stock Continues to Climb - Orange County Business Journal
Eledon Pharmaceuticals Earnings Notes - Trefis
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Midday Stock Roundup: Rivian Rises on Chip, Models - Orange County Business Journal
Eledon Pharmaceuticals stock drops after pricing $50M public offering By Investing.com - Investing.com Nigeria
Net current asset value per share of Eledon Pharmaceuticals, Inc. – DUS:2TK - TradingView — Track All Markets
Kidney Transplant Rejection Market on Track for Major Expansion by 2034, According to DelveInsight | GE Healthcare, Viela Bio, Eledon Pharma, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor - Barchart.com
Kidney Transplant Rejection Market on Track for Major Expansion - openPR.com
Eledon Pharmaceuticals Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Free Stock Index Interpretations - earlytimes.in
Why Eledon Pharmaceuticals Inc. stock is favored by pension fundsQuarterly Portfolio Review & Daily Profit Focused Screening - Newser
How analysts revise price targets for Eledon Pharmaceuticals Inc. (2TK) stockRisk Management & High Conviction Trade Alerts - Newser
Published on: 2025-12-04 05:40:36 - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Is Eledon Pharmaceuticals Inc. (2TK) stock attractive post correctionBond Market & Verified High Yield Trade Plans - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock stays on buy lists2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Eledon Pharmaceuticals (ELDN) Stock Analysis Report | Financials & Insights - Benzinga
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - The Manila Times
What drives Eledon Pharmaceuticals Inc stock priceInflation Impact on Stocks & Capital Growth Strategies - earlytimes.in
Midday Stock Roundup: Eledon Up 4.8% - Orange County Business Journal
FY2025 Earnings Forecast for ELDN Issued By Leerink Partnrs - MarketBeat
United StatesMintz Advises On Eledon Pharmaceuticals’ $50 Million Follow-on Offering - Mondaq
Eledon Shares Fall Nearly 50% After Phase 2 Results - Orange County Business Journal
What is Eledon Pharmaceuticals Inc (ELDN) Stock Return on Shareholders’ Capital? - setenews.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):